Showing 3131-3140 of 5614 results for "".
- Uneven Mental Health Staffing Undermines Access to Carehttps://reachmd.com/news/uneven-mental-health-staffing-undermines-access-to-care/2475177/After a period of unprecedented strain, mental health teams nationwide have regained pre-pandemic staffing levels, yet continue to w
- Enhancing Oncologic Surgery Precision with Real-Time ICG Fluorescence Imaginghttps://reachmd.com/news/enhancing-oncologic-surgery-precision-with-real-time-icg-fluorescence-imaging/2475179/Oncologic surgeons performing salvage resection for recurrent nasopharyngeal carcinoma often grapple with the imprecise delineation of tumor margins using conventional imaging modalities, raising the risk of incomplete excisions and suboptima
- SkinSpirit Shows Pride Month Support with $10,000 Donation to The Trevor Projecthttps://reachmd.com/news/skinspirit-shows-pride-month-support-with-10000-donation-to-the-trevor-project/2475383/June kicked off Pride month in the United States and national medspa chain SkinSpirit is showing support through its philanthropic arm, SS Gives. SkinSpirit is donating $10,000 to The Trevor Project. “At SkinSpirit, one of our core values is leading with love,” Lynn Heublein, the co- foun
- Emerging Advancements in Personalized Lung Cancer Treatmenthttps://reachmd.com/news/emerging-advancements-in-personalized-lung-cancer-treatment/2475155/Emerging advancements in lung cancer treatment, such as investigational nanoparticle genetic therapies and exploratory ctDNA analysis, are beginning to influence personalized medicine strategies, although they remain largely in early stages o
- Merging Nutritional and Molecular Strategies in Metabolic Disorder Managementhttps://reachmd.com/news/merging-nutritional-and-molecular-strategies-in-metabolic-disorder-management/2475157/Clinicians are witnessing the convergence of molecular tracers and nutritional science to tackle the complexities of metabolic disorders, with glucagon isotopes illuminating elusive pancreatic alpha cell behavior in Type 1 diabetes, while nat
- Post-Hepatitis C Cure: Unmasking the Threat of Metabolic Associated Steatotic Liver Disease in Liver Cancer Riskhttps://reachmd.com/news/post-hepatitis-c-cure-unmasking-the-threat-of-metabolic-associated-steatotic-liver-disease-in-liver-cancer-risk/2475096/While clearing Hepatitis C virus (HCV) marks a major milestone, Metabolic Associated Steatotic Liver Disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), emerges as a stealth driver of Hepatocellular Carcinoma (HCC) r
- Redefining Coronary Artery Disease Intervention: Novel Approaches in Pharmacology, Surgery, and Imaginghttps://reachmd.com/news/redefining-coronary-artery-disease-intervention-novel-approaches-in-pharmacology-surgery-and-imaging/2475034/Clinicians have long grappled with the narrow therapeutic window of antiplatelet therapy in coronary artery disease, where the protection against thrombosis with aspirin comes at the cost of residual ischemic events and potent alternatives ra
- Integrating Translational Science Breakthroughs in Alzheimer's Carehttps://reachmd.com/news/integrating-translational-science-breakthroughs-in-alzheimers-care/2475028/Clinicians face a narrowing window to integrate translational science breakthroughs and biomarker innovations that are reshaping Alzheimer's care, from the earliest diagnostic intervals to emerging targeted therapies. Current diagnosti
- Integrating Lifestyle Modifications in Colon Cancer Care: A New Paradigmhttps://reachmd.com/news/integrating-lifestyle-modifications-in-colon-cancer-care-a-new-paradigm/2474937/Emerging data suggest that targeted lifestyle adjustments—namely structured exercise regimens and anti-inflammatory diets—are associated with extended survival in colon cancer patients. However, these findings are based on observational studi
- FDA Approval of Risankizumab: A New Era for Ulcerative Colitis Treatmenthttps://reachmd.com/news/fda-approval-of-risankizumab-a-new-era-for-ulcerative-colitis-treatment/2474948/As gastroenterologists navigate the unmet needs of refractory ulcerative colitis, the FDA approval of risankizumab for ulcerative colitis marks a watershed